<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33479441</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Jan</Month><Day>21</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>1978</StartPage><MedlinePgn>1978</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1978</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-021-81599-5</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) patients express significant clinical heterogeneity that often hinders a correct diagnostic definition. Intracellular deposition of TDP-43, a protein involved in RNA metabolism characterizes the pathology. Interestingly, this protein can be detected in serum, wherein cognate naturally-occurring auto-antibodies (anti-TDP-43 NAb) might be also present, albeit they have never been documented before. In this exploratory study, we quantified the levels of both anti-TDP-43 NAb and TDP-43 protein as putative accessible markers for improving the ALS diagnostic process by using ELISA in N&#x2009;=&#x2009;70 ALS patients (N&#x2009;=&#x2009;4 carrying TARDBP mutations), N&#x2009;=&#x2009;40 age-comparable healthy controls (CTRL), N&#x2009;=&#x2009;20 motor neuron disease mimics (MN-m), N&#x2009;=&#x2009;20 Alzheimer's disease (AD) and N&#x2009;=&#x2009;15 frontotemporal lobar degeneration (FTLD) patients. Anti-TDP-43 NAb were found to be significantly increased in ALS patients compared to all the other groups (p&#x2009;&lt;&#x2009;0.001). On the other hand, the distribution of serum levels of TDP-43 protein was highly variable among the various groups. Levels were increased in ALS patients, albeit the highest values were detected in MN-m patients. NAb and protein serum levels failed to correlate. For the first time, we report that serum anti-TDP-43 NAb are detectable in human serum of both healthy controls and patients affected by a variety of neurodegenerative disorders; furthermore, their levels are increased in ALS patients, representing a potentially interesting trait core marker of this disease. Further studies are needed to clarify the exact role of the NAb. This information might be extremely useful for paving the way toward targeting TDP-43 by immunotherapy in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conti</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sala</LastName><ForeName>Gessica</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Diamanti</LastName><ForeName>Susanna</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, "San Gerardo" Hospital, ASST Monza, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casati</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Chemical and Clinical Analyses, "San Gerardo" Hospital, ASST Monza, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerardi</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarlarini</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEuroMuscular Omnicentre (NEMO), Fondazione Serena Onlus, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosca</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Genetics Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falzone</LastName><ForeName>Yuri</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filippi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurology Unit, Neurorehabilitation Unit, Neurophysiology Service, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroimaging Research Unit, Division of Neuroscience, IRCCS "San Raffaele" Scientific Institute, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vita-Salute San Raffaele University, Milano, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appollonio</LastName><ForeName>Ildebrando</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, "San Gerardo" Hospital, ASST Monza, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrarese</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, "San Gerardo" Hospital, ASST Monza, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tremolizzo</LastName><ForeName>Lucio</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Lab of Neurobiology, School of Medicine and Surgery and Milan Center for Neuroscience, University of Milano-Bicocca, Monza, Italy. lucio.tremolizzo@unimib.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit, "San Gerardo" Hospital, ASST Monza, Monza, Italy. lucio.tremolizzo@unimib.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, Room 2043, U8 building, Via Cadore 48, 20900, Monza, MB, Italy. lucio.tremolizzo@unimib.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000888">Antibodies, Anti-Idiotypic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000888" MajorTopicYN="N">Antibodies, Anti-Idiotypic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="N">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016472" MajorTopicYN="N">Motor Neuron Disease</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>22</Day><Hour>6</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33479441</ArticleId><ArticleId IdType="pmc">PMC7820419</ArticleId><ArticleId IdType="doi">10.1038/s41598-021-81599-5</ArticleId><ArticleId IdType="pii">10.1038/s41598-021-81599-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert. Opin. Ther. Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, et al. Cytoplasmic accumulation of TDP-43 in circulating lymphomonocytes of ALS patients with and without TARDBP mutations. Acta Neuropathol. 2011;121:611&#x2013;622. doi: 10.1007/s00401-010-0786-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-010-0786-7</ArticleId><ArticleId IdType="pubmed">21120508</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G, et al. Monocytes of patients with amyotrophic lateral sclerosis linked to gene mutations display altered TDP-43 subcellular distribution. Neuropathol. Appl. Neurobiol. 2017;43:133&#x2013;153. doi: 10.1111/nan.12328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12328</ArticleId><ArticleId IdType="pubmed">27178390</ArticleId></ArticleIdList></Reference><Reference><Citation>Arosio A, et al. HSC70 expression is reduced in lymphomonocytes of sporadic ALS patients and contributes to TDP-43 accumulation. Amyotroph. Lateral Scler. Frontotemp. Degener. 2020;21:51&#x2013;62. doi: 10.1080/21678421.2019.1672749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1672749</ArticleId><ArticleId IdType="pubmed">31663379</ArticleId></ArticleIdList></Reference><Reference><Citation>Beers DR, Appel SH. Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies. Lancet Neurol. 2019;18:211&#x2013;220. doi: 10.1016/S1474-4422(18)30394-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30394-6</ArticleId><ArticleId IdType="pubmed">30663610</ArticleId></ArticleIdList></Reference><Reference><Citation>Thundyil J, Lim KL. DAMPs and neurodegeneration. Ageing Res. Rev. 2015;24:17&#x2013;28. doi: 10.1016/j.arr.2014.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2014.11.003</ArticleId><ArticleId IdType="pubmed">25462192</ArticleId></ArticleIdList></Reference><Reference><Citation>Rezu&#x15f; E, et al. Inactivity and skeletal muscle metabolism: A vicious cycle in old age. Int. J. Mol. Sci. 2020 doi: 10.3390/ijms21020592.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21020592</ArticleId><ArticleId IdType="pmc">PMC7014434</ArticleId><ArticleId IdType="pubmed">31963330</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu BX, et al. Beta-amyloid auto-antibodies are reduced in Alzheimer's disease. J. Neuroimmunol. 2014;274:168&#x2013;173. doi: 10.1016/j.jneuroim.2014.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jneuroim.2014.06.017</ArticleId><ArticleId IdType="pmc">PMC4410718</ArticleId><ArticleId IdType="pubmed">25022335</ArticleId></ArticleIdList></Reference><Reference><Citation>Akhtar RS, et al. Measurements of auto-antibodies to &#x3b1;-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease. J. Neurochem. 2018;145:489&#x2013;503. doi: 10.1111/jnc.14330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.14330</ArticleId><ArticleId IdType="pmc">PMC6030437</ArticleId><ArticleId IdType="pubmed">29500813</ArticleId></ArticleIdList></Reference><Reference><Citation>Dodel R, et al. Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J. Neurosci. 2011;31:5847&#x2013;5854. doi: 10.1523/JNEUROSCI.4401-10.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4401-10.2011</ArticleId><ArticleId IdType="pmc">PMC6622820</ArticleId><ArticleId IdType="pubmed">21490226</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti E, et al. Cholinesterase inhibitor use is associated with increased plasma levels of anti-Abeta 1&#x2013;42 antibodies in Alzheimer's disease patients. Neurosci. Lett. 2010;486:193&#x2013;196. doi: 10.1016/j.neulet.2010.09.050.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.09.050</ArticleId><ArticleId IdType="pubmed">20869427</ArticleId></ArticleIdList></Reference><Reference><Citation>Verstraete E, et al. TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2012;13:446&#x2013;451. doi: 10.3109/17482968.2012.703208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/17482968.2012.703208</ArticleId><ArticleId IdType="pubmed">22873561</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph. Lateral Scler. Frontotemp. Degener. 2014;15:351&#x2013;356. doi: 10.3109/21678421.2014.905606.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.905606</ArticleId><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubois B, et al. Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol. 2014;13:614&#x2013;629. doi: 10.1016/S1474-4422(14)70090-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(14)70090-0</ArticleId><ArticleId IdType="pubmed">24849862</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol. Neurobiol. 2018;55:7789&#x2013;7801. doi: 10.1007/s12035-018-0947-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-018-0947-6</ArticleId><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Besser LM, Teylan MA, Nelson PT. Limbic predominant age-related TDP-43 encephalopathy (LATE): Clinical and neuropathological associations. J. Neuropathol. Exp. Neurol. 2020;79:305&#x2013;313. doi: 10.1093/jnen/nlz126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlz126</ArticleId><ArticleId IdType="pmc">PMC7036651</ArticleId><ArticleId IdType="pubmed">31845964</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozzi S, et al. Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology. J. Clin. Invest. 2019;129:1581&#x2013;1595. doi: 10.1172/JCI123931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI123931</ArticleId><ArticleId IdType="pmc">PMC6436898</ArticleId><ArticleId IdType="pubmed">30667370</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong QX, Zhu J, Liu SY, Yu XL, Liu RT. An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS. Int. Immunopharmacol. 2018;65:413&#x2013;421. doi: 10.1016/j.intimp.2018.10.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2018.10.032</ArticleId><ArticleId IdType="pubmed">30388515</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Q, et al. Antibodies inhibit transmission and aggregation of. EMBO Mol. Med. 2017;9:687&#x2013;702. doi: 10.15252/emmm.201607054.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/emmm.201607054</ArticleId><ArticleId IdType="pmc">PMC5412769</ArticleId><ArticleId IdType="pubmed">28351931</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti E, et al. Donepezil modulates the endogenous immune response: implications for Alzheimer's disease. Hum. Psychopharmacol. 2016;31:296&#x2013;303. doi: 10.1002/hup.2538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hup.2538</ArticleId><ArticleId IdType="pubmed">27297668</ArticleId></ArticleIdList></Reference><Reference><Citation>Chantran Y, Capron J, Alamowitch S, Aucouturier P. Anti-A&#x3b2; antibodies and cerebral amyloid angiopathy complications. Front. Immunol. 2019;10:1534. doi: 10.3389/fimmu.2019.01534.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01534</ArticleId><ArticleId IdType="pmc">PMC6620823</ArticleId><ArticleId IdType="pubmed">31333665</ArticleId></ArticleIdList></Reference><Reference><Citation>Britschgi M, et al. Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc. Natl. Acad. Sci. USA. 2009;106:12145&#x2013;12150. doi: 10.1073/pnas.0904866106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0904866106</ArticleId><ArticleId IdType="pmc">PMC2715538</ArticleId><ArticleId IdType="pubmed">19581601</ArticleId></ArticleIdList></Reference><Reference><Citation>Folke J, et al. Distinct autoimmune anti-&#x3b1;-synuclein antibody patterns in multiple system atrophy and Parkinson's disease. Front. Immunol. 2019;10:2253. doi: 10.3389/fimmu.2019.02253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02253</ArticleId><ArticleId IdType="pmc">PMC6769034</ArticleId><ArticleId IdType="pubmed">31616427</ArticleId></ArticleIdList></Reference><Reference><Citation>Hromadkova L, Ovsepian SV. Tau-reactive endogenous antibodies: origin, functionality, and implications for the pathophysiology of Alzheimer's disease. J. Immunol. Res.. 2019;2019:7406810. doi: 10.1155/2019/7406810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/7406810</ArticleId><ArticleId IdType="pmc">PMC6811779</ArticleId><ArticleId IdType="pubmed">31687413</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M, Tamaki Y, Hikiami R, Minamiyama S. Immunotherapy against misfolded proteins in ALS. Brain Nerve. 2019;71:1289&#x2013;1301. doi: 10.11477/mf.1416201439.</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416201439</ArticleId><ArticleId IdType="pubmed">31722315</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>